The Skin as a Living Ecosystem: Why Your Skin Condition Isn’t What You Think It Is.

Microbiome, Terrain, and Skin Disease

“The skin is not an organ you simply treat. It is an organ you interpret.”

Most people learn to think about skin disease as a surface problem. Identify the organism. Remove it. Repair the skin.

That approach isn’t entirely wrong. But it is incomplete.

Research published over the past decade — across dermatology, microbiology, and metabolic medicine — describes something very different. Your skin is not a passive surface being attacked by microbes. It is a living ecosystem, one of the most complex and carefully regulated systems in the human body.

Across your skin surface lives an enormous microbial community: bacteria, fungi, viruses, and even microscopic mites. In healthy physiology, these organisms are not simply tolerated. Many of them actively protect you.

They produce antimicrobial compounds. They compete with invasive species. They interfere with the signalling mechanisms pathogens use to establish infection.

This is not passive coexistence. It is continuous, active defence.

So the important question isn’t which organism is present. The important question is: why does that organism gain advantage?

The answer is terrain.

pH. Lipid composition. Immune signalling. The metabolic and hormonal state of the host.

When the terrain is stable, the ecosystem remains balanced. When the terrain shifts, certain organisms proliferate. That shift is called dysbiosis — and dysbiosis is downstream of the terrain. It is the consequence, not the starting point.

That distinction changes how we think about virtually every common inflammatory skin condition.

This post is the foundation. Acne vulgaris, atopic dermatitis, seborrhoeic dermatitis, and rosacea each deserve their own dedicated deep-dive — and they’ll get one. But first, we build the framework that underpins all of them.

What the Real World Tells Us

Before the molecular science, six real-world observations that make the terrain argument hard to ignore.

1. Isolated populations with no recorded acne

A 2002 study published in Archives of Dermatology examined 1,200 subjects from the Kitavan people of Papua New Guinea and the Ache hunter-gatherers of Paraguay — both isolated from Western diet and modern skincare products. Findings: zero clinical cases of acne across the entire cohort. Zero. The proposed mechanism: a low-glycaemic diet and absence of insulin-stimulating processed foods maintained sebum production at a level that did not create conditions for C. acnes dysbiosis. The terrain did not shift. The condition did not develop.

2. The COVID-19 sanitisation wave

When hand sanitisers and disinfectants became universal in 2020, dermatology practices globally documented a rapid rise in contact dermatitis, eczema flares, and barrier disruption. Aggressive removal of surface organisms — including commensals — combined with repeated alcohol-based lipid-stripping of the skin surface shifted the terrain. The protective microbial community was depleted. The barrier chemistry was disrupted. The clinical consequence appeared at population scale.

3. UV therapy and host environment modification

Before modern antibiotics, early 20th century hospitals used ultraviolet light therapy to treat certain skin infections and inflammatory dermatoses — with documented efficacy. Narrowband UVB therapy, still used in dermatology today, has documented immunomodulatory effects that extend beyond vitamin D alone. UV exposure alters T-cell signalling, cytokine expression, keratinocyte behaviour, and antimicrobial peptide production. It modifies the host environment — and when the host environment shifts, microbial ecology shifts.

4. Type 2 diabetes and the skin as a metabolic mirror

Patients with type 2 diabetes have substantially higher rates of fungal skin infections, bacterial skin infections, impaired wound healing, and specific dermatological conditions — including acanthosis nigricans (dark, velvety patches in body folds, often the first visible marker of insulin resistance before a formal diagnosis is even made) and necrobiosis lipoidica. The skin is reflecting the systemic metabolic state before the blood tests do. These are not separate diseases. They are downstream skin manifestations of a disrupted internal terrain.

5. Coeliac disease and dermatitis herpetiformis

Dermatitis herpetiformis is a specific blistering skin rash that develops as a direct extraintestinal manifestation of coeliac disease — an autoimmune intolerance to gluten. No skin infection is involved. A dietary trigger produces gut immune dysregulation, which produces a specific, reproducible skin rash through systemic immune signalling — IgA antibody deposition in the papillary dermis. Treatment: remove gluten. The skin clears. The most direct documented example of the gut-skin axis as a clinical reality.

6. Indoor environments and skin infection rates

Populations with predominantly indoor lifestyles consistently show higher rates of skin infections and S. aureus colonisation. Multiple converging factors: reduced UV exposure, reduced environmental microbial diversity, and the metabolic consequences of sedentary behaviour including insulin resistance. The skin ecosystem does not exist in isolation from the body or the external environment.

What these six observations share is a pattern: when the conditions that support skin ecosystem balance are disrupted — whether through diet, hygiene practice, UV exposure, metabolic health, or gut function — the skin reflects it. The terrain is the underlying story.

Your Microbiome Begins at Birth

Your skin microbiome does not begin at puberty, or at the first skin condition. It begins at the moment of birth.

In the womb, a fetus is sterile. The first colonisation of the skin surface happens during delivery — and how you are born has a measurable effect on your initial microbial community.

If the birth is vaginal: the baby passes through the birth canal and acquires a community dominated by vaginal microorganisms from the mother — organisms including Lactobacillus, Prevotella, and Sneathia, strongly associated with protective, anti-inflammatory environments.

If the birth is by caesarean section: the baby is not exposed to the birth canal microbiome. Instead, the founding community more closely resembles the mother’s skin surface — dominated by Staphylococcus, Corynebacterium, and Cutibacterium. These are normal skin commensals, but the composition differs meaningfully.

This is not a commentary on birth method — caesarean sections are medically necessary and life-saving in many circumstances. It is a demonstration of how early and how strongly biological context shapes the microbial environment.

After birth, the microbiome continues developing. Breastfeeding transfers maternal microorganisms via milk and skin contact. Adolescence brings the next major shift — rising androgen levels during puberty increase sebum production in sebaceous regions. Sebum is the primary nutrient source for lipophilic bacteria, particularly Cutibacterium. This explains the tight link between puberty and acne.

Adulthood is the stable phase — though “stable” is relative. The microbiome shifts continuously with lifestyle, diet, medications, climate, UV exposure, and age. Microbial turnover is greater in dry skin areas than in oily areas, suggesting the lipid-rich sebaceous sites create more stable ecological niches.

Who Lives on Your Skin

The distribution of organisms across the skin is not random. It follows the physical and chemical landscape of each microenvironment.

Sebaceous (oily) areas — face, scalp, upper chest and back — are dominated by Cutibacterium, the lipid-consuming bacterium. Moist areas — armpits, groin, the inner elbow — are dominated by Staphylococcus and Corynebacterium species. Dry areas — forearms, legs — by Micrococcus, Streptococcus, and Corynebacterium.

The bacterial residents worth knowing:

Cutibacterium acnes (C. acnes) lives primarily in sebaceous follicles. In healthy conditions it metabolises fatty acids, produces antimicrobial compounds including bacteriocins (natural antibiotics), and maintains the skin’s acidic pH — the range that inhibits most pathogens. In balanced conditions: a protective commensal. When the terrain shifts: an opportunistic contributor to acne.

Staphylococcus epidermidis is the most consistently present bacterial species on human skin. It produces antimicrobial peptides active against Group A Streptococcus and S. aureus — the skin’s primary resident sentinel organism.

Staphylococcus aureus — in healthy individuals, absent or in very low numbers. Held in check by its commensal neighbours. Its overgrowth is a sign the ecosystem has already been disrupted — not the starting point.

The fungal resident:

Malassezia accounts for 50 to 80 percent of the total fungal community on healthy skin. It cannot synthesise its own fatty acids — making it entirely dependent on the host’s sebum. In normal conditions: a commensal that contributes to the skin’s chemical ecology. When the terrain shifts: associated with dandruff, pityriasis versicolor, seborrhoeic dermatitis, and atopic dermatitis.

The arthropod resident:

Demodex folliculorum is a microscopic mite that lives head-first in sebaceous hair follicles, feeding on sebum and epithelial cells. Virtually every adult carries Demodex. A commensal at normal density. In rosacea, particularly the papulopustular subtype, densities are elevated and contribute to inflammation.

The viral layer:

The skin also carries a virome — the viral community — though it is the least-characterised component. Herpes simplex virus establishes latency in nerve ganglia and reactivates during periods of stress, immune suppression, or barrier disruption. In the context of atopic dermatitis, HSV-1 reactivation can cause eczema herpeticum — a serious widespread viral skin infection that occurs specifically because the skin barrier and immune landscape have been disrupted by chronic eczema.

Bacteriophages — viruses that infect bacteria, not human cells — are the most abundant viral entities on the skin surface. They regulate bacterial population dynamics by infecting and lysing bacterial cells, playing an ecological role in controlling community composition.

The Defence Network

The scientific term for what I want to walk you through now is colonisation resistance — the ability of the resident microbial community to prevent pathogens from establishing themselves on the skin. The mechanisms behind it are now well-characterised, and they are more sophisticated than most clinical training conveys.

Bacteriocins — your skin’s own antibiotic production

The commensal staphylococci produce bacteriocins: small antimicrobial peptides that inhibit competing organisms. A single screening study of healthy skin isolates found 21 distinct bacteriocins with activity against clinically significant pathogens.

S. epidermidis produces Epidermin and Epilancin K7, active against MRSA and other resistant organisms. S. capitis produces Nisin J and S. hominis produces MP1 — both with documented activity against penicillin-resistant Streptococcus, vancomycin-resistant enterococci (VRE), and multiple MRSA strains.

Your commensal skin bacteria are producing molecules that target treatment-resistant hospital pathogens. Continuously.

Staphylococcus lugdunensis produces Lugdunin — a cyclic peptide antibiotic that prevents S. aureus colonisation at the skin surface and in deeper tissue layers. Animal models show significant or complete S. aureus eradication following lugdunin application.

Short-chain fatty acids — metabolic competition

Both C. acnes and S. epidermidis ferment glycerol — a compound naturally present in sebum — producing short-chain fatty acids (SCFAs): acetic, propionic, and butyric acid. These maintain the skin’s acidic pH (4.5–5.5) — the range at which most pathogens cannot establish themselves — and directly inhibit pathogen growth.

C. acnes-derived propionic acid has been shown to suppress MRSA colonisation of skin lesions. S. epidermidis-derived SCFAs inhibit C. acnes growth. Each organism keeps the other in check through metabolic chemistry. This reciprocal balance is a core feature of the healthy skin ecosystem.

C. acnes SCFAs also inhibit S. epidermidis biofilm formation. Biofilms are the protective matrix bacteria construct to resist antibiotics — organisms within a biofilm can be up to 1,000 times harder to treat. Preventing their formation is a significant ecological advantage.

Protease enzymes — dismantling pathogen architecture

Proteases are enzymes that break down proteins, and commensals deploy them to physically dismantle pathogen structures. S. epidermidis produces a protease called Esp that disrupts S. aureus biofilms by cleaving specific adhesion proteins — removing S. aureus’s primary resistance shield.

Malassezia globosa produces a protease called MgSAP1 that cleaves Protein A — a major virulence factor that S. aureus uses to evade immune clearance. MgSAP1 expression has been documented on the skin of virtually all healthy volunteers tested: continuously expressed, not just triggered. Your resident fungal population is routinely stripping S. aureus of one of its primary immune evasion weapons.

In atopic dermatitis, M. globosa abundance is measurably reduced — the same patients whose skin is characteristically colonised by S. aureus. The ecological correlation is consistent.

Quorum sensing interference — disabling pathogen communication

This is perhaps the most remarkable mechanism. Quorum sensing is the cell-to-cell communication system bacteria use to coordinate population behaviour. When S. aureus reaches a critical density, its Agr (accessory gene regulator) system triggers a coordinated release of toxins, proteases, and inflammatory factors — the mechanism driving tissue damage in serious S. aureus infections and atopic dermatitis flares.

When density increases, virulence activates.

Commensal species block that signal. They silence the attack before it begins.

S. epidermidis, S. hominis, S. caprae, and S. simulans produce autoinducer peptides (AIPs) that bind to the S. aureus Agr receptor without activating it — occupying the signal site and silencing the cascade.

In clinical studies of atopic dermatitis, patients with higher disease severity showed lower abundance of S. epidermidis Agr type I — the subtype that blocks S. aureus signalling. In mouse models, topical AIP application reduced dermonecrosis (skin tissue death from S. aureus toxins).

There is also a striking finding involving Corynebacterium striatum: when S. aureus is co-cultured with C. striatum, its gene expression profile shifts away from virulence genes and toward genes associated with commensal behaviour. The presence of the right community members changes what S. aureus does entirely.

What Disrupts the Terrain

Dysbiosis does not have a single upstream cause. This is one of the most clinically important points here, because it explains why a treatment that works for one patient may not work for another with the same skin condition — and why recurrence is common when only the visible dysbiosis is addressed without understanding what shifted the terrain.

Hormones shift the terrain. Sebum production is primarily regulated by androgens — testosterone and dihydrotestosterone (DHT). Elevated androgen activity — from puberty, PCOS, hormonal contraceptive changes, or androgen excess from other causes — increases sebum output, creating a richer nutrient environment in hair follicles and sebaceous glands. C. acnes and Malassezia proliferate accordingly.

Insulin shifts the terrain. Elevated insulin — from high glycaemic dietary patterns, insulin resistance, or metabolic syndrome — stimulates sebaceous glands independently of androgens, and elevates IGF-1. A 2023 meta-analysis of 37 studies found a pooled odds ratio of 3.28 between metabolic syndrome and skin diseases. Seborrhoeic dermatitis had an odds ratio of 2.45.

Thyroid dysfunction shifts the terrain. Hypothyroidism reduces skin cell turnover, reduces sebum production, and produces dry, thick, rough skin with impaired barrier function. Hyperthyroidism produces warm, sweaty, thin skin with altered sebum profiles. Both shifts change the chemical and moisture landscape that commensal organisms inhabit.

Gut inflammation shifts the terrain. The gut microbiome exerts systemic immune effects. When the gut is dysregulated, systemic low-grade inflammation can manifest in the skin. Specific documented associations: coeliac disease → dermatitis herpetiformis, SIBO → rosacea (antibiotic treatment of SIBO has been shown to improve rosacea in a subset of patients), and dairy — particularly milk and whey protein — consistently associated with acne severity in meta-analyses. Notably, fermented dairy does not carry the same association, because fermentation reduces the insulin-stimulating mTORC1 signalling.

Vitamin D deficiency shifts the terrain. Vitamin D plays specific roles in skin barrier gene expression and in the production of antimicrobial peptides by keratinocytes. Deficiency is associated with increased atopic dermatitis severity and increased susceptibility to skin infection.

Medications and skincare shift the terrain. Long-term oral antibiotics — commonly prescribed for acne — reduce the commensal staphylococcal population that produces bacteriocins, regulates quorum sensing, and maintains ecological balance. Antibiotic resistance in C. acnes is a documented and growing clinical problem, precisely because these treatments affect the full ecosystem, not only the target organism. Alkaline cleansers, harsh surfactants, and overuse of topical corticosteroids alter the skin’s chemical terrain — not an argument against their appropriate use, but context for understanding the full picture when patients are not responding as expected.

Four Conditions Through the Terrain Lens

Each of the major inflammatory skin conditions deserves its own full post. But briefly — here is the pattern applied.

Acne vulgaris is not an infection. It is follicular terrain collapse. The follicular terrain shifts — driven by androgen excess, insulin signalling, dietary factors, or gut dysbiosis — creating an anaerobic, nutrient-rich environment in which specific C. acnes strains bloom disproportionately. The inflammatory response follows from that dysbiosis.

Atopic dermatitis begins with barrier disruption — typically with a genetic component involving reduced ceramide production and filaggrin gene mutations. Disrupted barrier shifts pH alkaline, impairs antimicrobial peptide function, depletes commensal staphylococci, and creates conditions for S. aureus overgrowth and Agr quorum sensing activation. In children, the pattern of S. aureus colonisation beginning in early infancy before the onset of visible eczema suggests that microbiome disruption precedes and contributes to barrier disease.

Seborrhoeic dermatitis involves Malassezia dysbiosis on a background of altered sebum lipid composition, insulin resistance, and impaired barrier function — predominantly affecting the scalp, face, and chest.

Rosacea involves the convergence of multiple factors: Demodex overgrowth, innate immune hyperactivation, gut dysbiosis including the SIBO association, and highly individual environmental triggers. No single cause holds across all patients.

Where the Science Is Going

Conventional dermatology has produced genuinely effective treatments — topical steroids, antibiotics, antifungals, retinoids, and biologics are well-validated and improve quality of life for millions of patients. The ecological framework does not replace them. It adds a layer of reasoning that helps explain non-response, recurrence, and what else might be contributing in individual patients.

The research trajectory is pointing toward microbiome restoration.

Autologous microbiome transplants in atopic dermatitis: commensal staphylococci isolated from a patient’s own healthy skin, cultured, and reapplied to lesional skin. S. aureus reduction demonstrated without antibiotics. (Nakatsuji et al., 2017.)

Roseomonas mucosa — first-in-human topical trial in atopic dermatitis: live R. mucosa application improved barrier function, activated innate immunity, and reduced steroid requirements. The effect required live bacteria — dead cells and supernatant alone did not replicate it. (Myles et al., 2018.)

Topical Lactobacillus probiotic formulations in acne: phase II clinical trials showed reductions in inflammatory lesions and microbiome modulation persisting four weeks after the end of treatment. (Lebeer et al., 2022.)

Quorum sensing inhibitors — synthetic AIPs that block S. aureus’s Agr communication as antivirulence therapy. Targets the organism’s weapons rather than the organism, theoretically reducing antibiotic resistance selection pressure. (Williams et al., 2019.)

Three Things to Carry Forward

One. Your skin is an active ecosystem. The organisms living on it produce documented natural antibiotics, dismantle pathogen architecture, and silence the communication signals harmful bacteria use to mount attacks. When the ecosystem is intact, these mechanisms are working continuously on your behalf.

Two. The terrain determines the microbiome. Hormones, metabolism, diet, gut health, thyroid function, vitamin D, UV exposure, medications, and skincare all shape the environment. Dysbiosis is the visible downstream effect. The terrain is the underlying story. Addressing only the dysbiosis without understanding the terrain is managing the effect, not the cause.

Three. The science is moving toward ecological medicine — restoring function rather than simply suppressing organisms. Microbiome transplantation, targeted probiotic therapy, and quorum sensing interference are moving through clinical trials. The molecular biology supports this direction, and the early clinical results are promising.

Coming up next: dedicated posts on acne vulgaris, atopic dermatitis, seborrhoeic dermatitis, and rosacea — each condition examined in full clinical and microbiological detail through this framework.

References

Glatthardt T, Lima RD, de Mattos RM, Ferreira RBR. Microbe Interactions within the Skin Microbiome. Antibiotics 2024;13:49.

Condrò G, Guerini M, Castello M, Perugini P. Acne Vulgaris, Atopic Dermatitis and Rosacea: The Role of the Skin Microbiota — A Review. Biomedicines 2022;10:2523.

Cheng Y et al. Research Progress on the Exacerbation of Lipid Metabolism by Malassezia and Its Impact on the Skin Barrier Function. Cosmetics 2025;12:67.

Tripathy K, Dulai AS, Min M, Sivamani RK. Insulin Resistance, Metabolic Syndrome, and Inflammatory Skin Disease. J Clin Med 2026;15:330.

Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol. 2018;16:143–155.

Williams MR et al. Quorum sensing between bacterial species protects against epidermal injury in atopic dermatitis. Sci Transl Med. 2019;11:eaat8329.

Nakatsuji T et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus. Sci Transl Med. 2017;9:eaah4680.

Myles IA et al. First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis. JCI Insight. 2018;3:e120608.

Lebeer S et al. Selective targeting of skin pathobionts and inflammation with topically applied lactobacilli. Cell Rep Med. 2022;3:100521.

Iwase T et al. Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation. Nature. 2010;465:346–349.

Cordain L et al. Acne vulgaris: a disease of Western civilisation. Arch Dermatol. 2002;138:1584–1590.

Sodagar S et al. Association between metabolic syndrome and prevalent skin diseases: meta-analysis. Health Sci Rep. 2023;6:e1576.